NASDAQ:ADMA ADMA Biologics (ADMA) Stock Price, News & Analysis $18.59 +0.33 (+1.81%) Closing price 07/30/2025 04:00 PM EasternExtended Trading$18.73 +0.14 (+0.75%) As of 05:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ADMA Biologics Stock (NASDAQ:ADMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ADMA Biologics alerts:Sign Up Key Stats Today's Range$18.39▼$18.9250-Day Range$16.73▼$21.8752-Week Range$10.21▼$25.67Volume2.67 million shsAverage Volume2.25 million shsMarket Capitalization$4.44 billionP/E Ratio21.87Dividend YieldN/APrice Target$27.67Consensus RatingBuy Company Overview ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. Read More ADMA Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreADMA MarketRank™: ADMA Biologics scored higher than 76% of companies evaluated by MarketBeat, and ranked 255th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageADMA Biologics has only been the subject of 1 research reports in the past 90 days.Read more about ADMA Biologics' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth35.29% Earnings GrowthEarnings for ADMA Biologics are expected to grow by 35.29% in the coming year, from $0.51 to $0.69 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is 21.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.51.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is 21.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.19.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 12.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ADMA Biologics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.05% of the float of ADMA Biologics has been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in ADMA Biologics has recently increased by 17.60%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.05% of the float of ADMA Biologics has been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in ADMA Biologics has recently increased by 17.60%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment1.12 News SentimentADMA Biologics has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for ADMA Biologics this week, compared to 9 articles on an average week.Search InterestOnly 15 people have searched for ADMA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows21 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 24% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,644,269.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADMA Biologics' insider trading history. Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADMA Stock News HeadlinesADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025July 30 at 7:00 AM | globenewswire.comInvesting in ADMA Biologics (NASDAQ:ADMA) three years ago would have delivered you a 696% gainJuly 24, 2025 | finance.yahoo.comThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains. | Weiss Ratings (Ad)Heavy Insider Selling at ADMA Biologics Despite Earnings StrengthJuly 24, 2025 | finance.yahoo.comADMA Biologics, Inc. Rings the Opening BellJuly 15, 2025 | nasdaq.comIs ADMA Biologics Gaining or Losing Market Support?July 3, 2025 | benzinga.comADMA Biologics Inc Dividends - MorningstarJuly 2, 2025 | morningstar.comMImplied Volatility Surging for ADMA Biologics Stock OptionsJune 27, 2025 | finance.yahoo.comSee More Headlines ADMA Stock Analysis - Frequently Asked Questions How have ADMA shares performed this year? ADMA Biologics' stock was trading at $17.15 at the beginning of the year. Since then, ADMA stock has increased by 8.4% and is now trading at $18.59. How were ADMA Biologics' earnings last quarter? ADMA Biologics Inc (NASDAQ:ADMA) posted its quarterly earnings data on Wednesday, May, 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by $0.02. The firm's revenue for the quarter was up 40.2% compared to the same quarter last year. Read the conference call transcript. Who are ADMA Biologics' major shareholders? ADMA Biologics' top institutional shareholders include Allspring Global Investments Holdings LLC (1.39%), Perpetual Ltd (1.21%), Vaughan Nelson Investment Management L.P. (0.75%) and Aberdeen Group plc (0.22%). Insiders that own company stock include Adam S Grossman, Brian Lenz, Jerrold B Grossman, Kaitlin M Kestenberg-Messina, Young Kwon, Brad L Tade, Lawrence P Guiheen, Steve Elms and Bryant Fong. View institutional ownership trends. How do I buy shares of ADMA Biologics? Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/07/2025Today7/31/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADMA CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees530Year FoundedN/APrice Target and Rating Average Price Target for ADMA Biologics$27.67 High Price Target$32.00 Low Price Target$25.00 Potential Upside/Downside+48.8%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$0.85 Trailing P/E Ratio21.87 Forward P/E Ratio36.45 P/E GrowthN/ANet Income$197.67 million Net Margins45.01% Pretax Margin30.64% Return on Equity47.16% Return on Assets30.51% Debt Debt-to-Equity Ratio0.22 Current Ratio6.58 Quick Ratio3.36 Sales & Book Value Annual Sales$426.45 million Price / Sales10.41 Cash Flow$0.55 per share Price / Cash Flow33.74 Book Value$1.48 per share Price / Book12.56Miscellaneous Outstanding Shares238,730,000Free Float230,378,000Market Cap$4.44 billion OptionableOptionable Beta0.43 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ADMA) was last updated on 7/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.